DIABETES and COVID-19 [COVID-19]
Research type
Research Study
Full title
Data-driven Insights and Analysis to Better Estimate The Effect of Sugar in COVID-19: A retrospective observational study of outcomes and survival in those with diabetes and COVID-19
IRAS ID
284112
Contact name
Jackie Elliott
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
Clinicaltrials.gov Identifier
researchregistry5707, ; ,
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Research Summary
Coronavirus disease 2019 (CoVID-19) is an ongoing international pandemic and a pressing public emergency in the UK. Data from largely Chinese observational cohorts with small numbers suggests that people with diabetes develop severe infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) and have a poor prognosis to COVID-19. No conclusive data on outcomes in those with diabetes has been reported from a UK cohort.\n\nThis is retrospective case-control study of all COVID-19 admissions at Sheffield Teaching Hospitals aims to identify demographic, clinical and para-clinical risk markers that determine morbidity and mortality in COVID-19 in those with diabetes compared to those without diabetes. Anecdotal clinical experience suggests that patients with type 2 diabetes (T2D) in particular are presenting atypically with ketoacidosis and demonstrate profound insulin resistance with resultant inpatient hyperglycaemia. Hence this study further aims to develop a prospective risk stratification tool to gauge CoVID-19 severity in those with diabetes compared to those without diabetes.\n\nAll data collected as part of this study will be derived from clinical records collated as part of routine clinical care of CoVID-19 patients at Sheffield Teaching Hospitals. These data include demographics, past medical history, medications at admission and during hospital stay, clinical presentation, and laboratory and radiology data.Summary of Results
Patients with diabetes mellitus (DM) are significantly more like to die of coronavirus disease 2019 (COVID-19) when hospitalised with the disease. Unique factors that can be used, upon hospital admission, to predict COVID-19 mortality among DM patients have been identified. These are an increase in the time it takes for blood to clot (with or without anticoagulants), an increased neutrophil-lymphocyte ratio (a blood test used to assess inflammation) and elevated sodium in the blood. Interestingly, these markers were only associated with hospital COVID-19 mortality among DM patients.REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
20/EM/0145
Date of REC Opinion
29 May 2020
REC opinion
Favourable Opinion